Dual targeting of G9a and DNMT1 for the treatment of experimental cholangiocarcinoma.
Leticia ColynMarina Bárcena-VarelaGloria Álvarez-SolaM Ujue LatasaIker UriarteEva SantamaríaJose M HerranzAlvaro Santos-LasoMaria ArechederraMikel Ruiz de GaunaPatricia AspichuetaMatteo CanaleAndrea Casadei-GardiniMaria FrancesconiSimone CarottiSergio MoriniLeonard J NelsonMaria J IraburuChaobo ChenBruno SangroJose Jg MarinMaria L Martinez-ChantarJesus M BanalesRobert ArnesMeritxell HuchJohn PatinoAltaf A DarMehdi NosratiJulen OyarzábalFelipe PrósperJesus UrmanFrancisco Javier CuberoChristian TrautweinCarmen BerasainMaite G Fernandez-BarrenaMatias A AvilaPublished in: Hepatology (Baltimore, Md.) (2020)
Dual targeting of G9a and DNMT1 with epigenetic small molecule inhibitors such as CM272 is a potential novel strategy to treat CCA and/or to enhance the efficacy of other systemic therapies.
Keyphrases